产品中心 / 产品类型 / 重组蛋白 / TNF

活性验证

Recombinant Human TNFRSF21/DR6/CD358 Protein (RP01349)

Active Recombinant Human TNFRSF21/DR6 Protein was determined by SDS-PAGE with Coomassie Blue, showing a band at 95-100kDa.

Immobilized Human APP at 10 μg/mL (100 μL/well) can bind Mouse DR6 with a linear range of 0.002-1.8 μg/mL.

All(2)|
货号: RP01349
促销价:   ¥320
货    期:现货产品
抗体定制服务咨询 |
商城订购

详细信息

种属
Human
表达宿主
HEK293 cells
描述
Active Recombinant Human TNFRSF21/DR6 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Gln42-Leu350) of human TNFRSF21/DR6 (Accession #NP_055267.1) fused with a Fc, 6×His tag at the C-terminus.
标签
C-hFc&His
纯度
> 95% by SDS-PAGE.
内毒素
< 1 EU/μg of the protein by LAL method.
生物活性
Measured by its binding ability in a functional ELISA.Immobilized Human APP at 10 μg/mL (100 μL/well) can bind Mouse DR6 with a linear range of 0.002-1.8 μg/mL.
制剂
Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.
储存
Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt.
After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week.未开盖的干粉蛋白在 -20°C至-80°C可保存12个月;
复溶之后,蛋白溶液在-20°C及以下可保存3个月,在2-8℃可保存1周。
复溶
Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.收到重组蛋白产品之后请检查蛋白冻干粉末是否贴于瓶底,如果粉末浮起,开盖之前请先低温离心。将蛋白用说明书中指定的缓冲液复溶至0.1-0.5 mg/mL(请注意蛋白复溶浓度不能低于0.1 mg/mL),室温平衡5-10 min保证充分溶解,复溶过程中请不要剧烈涡旋及吹打蛋白溶液。如需长期储存,建议复溶时添加载体蛋白或者稳定剂(如0.1% BSA, 5% HSA, 10% FBS 或者 5% 海藻糖),同时将复溶后的蛋白溶液按照需求进行分装,储存于-20°C至-80°C,随取随用,避免反复冻融。

蛋白复溶计算器

请在蛋白复溶计算器中输入蛋白总质量和所需终浓度,快速计算您需要添加溶液的体积吧!
=
÷

背景信息

Tumor necrosis factor receptor superfamily member 21 (TNFRSF21) is also known as death receptor 6 (DR6), which is a member of the TNF-receptor superfamily.This type I transmembrane receptor possesses four extracellular cysteine-rich motifs and a cytoplasmic death domain. DR6 is an extensively posttranslationally modified transmembrane protein and that N- and O-glycosylations of amino acids in its extracellular part. DR6 interacts with the adaptor protein TRADD and mediates signal transduction through its death domain, and expression of DR6 in mammalian cells induces activation of both NF-kappaB and JNK and cell apoptosis. DR6 knockout mice have enhanced CD4+ T cell proliferation and Th2 cytokine production, suggested that DR6 serves as an important regulatory molecule in T-helper cell activation, and is involved in inflammation and immune regulation. DR6 is expressed ubiquitously with high expression in lymphoid organs, heart, brain and pancreas. Some tumor cells overexpress DR6, typically in conjunction with elevated anti-apoptosis molecules. DR6 may also be involved in tumor cell survival and immune evasion, which is subject to future investigations.

>